Top Markets
Coin of the day
Park Ha Biological Technology Co., Ltd. Park Ha Biological Technology Co., Ltd.

Park Ha Biological Technology Co., Ltd.

PHH
Clasificación en acciones #33156
Park Ha Biological Technology Co., Ltd., an investment holding firm, is... Park Ha Biological Technology Co., Ltd., an investment holding firm, is primarily engaged in the creation and development of skincare products within the People's Republic of China. The company's operations are divided into two core areas: direct product sales and a franchise service model. Under its own 'Park Ha' brand, the company offers a comprehensive selection of skincare solutions. These products cater to a spectrum of dermatological needs, ranging from fundamental physical skin protection and exfoliation to repairing the sebum film, achieving surface microecological balance, and providing anti-aging treatments. Park Ha Biological Technology distributes its merchandise to consumers through both its company-owned retail outlets and an extensive network of franchised partners. Established in 2016, the firm's main office is situated in Wuxi, PRC. It operates as a subsidiary of Xiaoqiu Holding Ltd.
Precio por acción
$0.2527
Última sincronización: 2025-11-24
Capitalización bursátil
$8.25M
Cambio (1 día)
-1.98%
Cambio (1 año)
-55.67%
País
CN
Comercio Park Ha Biological Technology Co., Ltd. (PHH)
Ganancias de Park Ha Biological Technology Co., Ltd. (PHH)
Ganancias en 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Park Ha Biological Technology Co., Ltd., gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, igual a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de Park Ha Biological Technology Co., Ltd. desde 2026 hasta 2026
Ganancias al final de cada año
Año Ganancias Cambiar
Not enough data for the provided dates.
Ganancias de empresas similares o competidoras
Empresa Ganancias Diferencia de ganancias País
$20.38B -
US
$9.83B -
FR
$2.94B -
US
$1.55B -
IN
- -
DE